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Crystal structures can identify ligand-receptor interactions and assist the development of novel thera-
peutics, but experimental challenges sometimes necessitate the use of homologous proteins. Tropisetron
is an orthosteric ligand at both 5-HT3 and a7 nACh receptors and its binding orientation has been
determined in the structural homologue AChBP (pdbid: 2WNC). Co-crystallisation with a structurally-
related ligand, granisetron, reveals an almost identical orientation (pdbid; 2YME). However, there is a
>1000-fold difference in the afﬁnity of tropisetron at 5-HT3 versus a7 nACh receptors, and a7 nACh
receptors do not bind granisetron. These striking pharmacological differences prompt questions about
which receptor the crystal structures most closely represent and whether the ligand orientations are
correct. Here we probe the binding orientation of tropisetron and granisetron at 5-HT3 receptors by in
silico modelling and docking, radioligand binding on cysteine-substituted 5-HT3 receptor mutants
transiently expressed in HEK 293 cells, and synthetic modiﬁcation of the ligands. For 15 of the 23
cysteine substitutions, the effects on tropisetron and granisetron were different. Structure-activity re-
lationships on synthesised derivatives of both ligands were also consistent with different orientations,
revealing that contrary to the crystallographic evidence from AChBP, the two ligands adopt different
orientations in the 5-HT3 receptor binding site. Our results show that even quite structurally similar
molecules can adopt different orientations in the same binding site, and that caution may be needed
when using homologous proteins to predict ligand binding.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Tropisetron (e.g. Navoban®, ICS 205-930), granisetron (e.g.
Kytril®, Sancuso®, Granisol™) and other structurally-related drugs
are used to alleviate the symptoms of nausea and vomitingCh, nicotinic acetylcholine;
yonic kidney; AChBP, acetyl-
diﬁed to resemble the 5-HT3R
gy, Tennis Court Road, Cam-
y and Molecular Medicine,
(M. Lochner), ajt44@cam.ac.
r Ltd. This is an open access articlefollowing general anaesthesia, cancer chemotherapy and radio-
therapy (Thompson, 2013). The therapeutic effect of these is due to
their high-afﬁnity competitive block of 5-HT3 receptors in the gut
and brain stem.
5-HT3 receptors belong to the Cys-loop family of trans-
membrane ligand-gated ion-channels that are responsible for fast
synaptic neurotransmission in the central and peripheral nervous
systems. All members of this family are composed of ﬁve subunits,
each of which contains an extracellular, a transmembrane and an
intracellular domain (Miller and Smart, 2012; Thompson et al.,
2010). Binding of tropisetron and granisetron to extracellular
binding sites blocks the action of the native agonist 5-HT. These
binding sites are at the interface of two adjacent subunits and form
a hydrophobic cavity that is composed of amino acids from loops A
- C in the principal subunit interface and loops D - F in the com-
plementary subunit interface (Fig. 1).under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Positions of the residues mutated in this study. (A) A cartoon showing the orthosteric binding site of the 5-HT3 receptor formed by binding loops AeF. The extracellular
binding site is found at the interface of two adjacent subunits. For clarity only two subunits are shown. (B) An amino acid sequence alignment showing the positions of mutated
residues (white text, black boxes). The six recognised binding loops are shown as grey lines. The proteins are sequences from human 5-HT3A (P46098), mouse 5-HT3A (Q6J1J7),
chick a7 nACh (F1P4Y5) and sequences taken from the AChBP crystal structures 2YME, 2WNC and 3SQ6. c_a7nACh and h_5HT3 are the sequences of receptors used in the binding
studies presented here. EMBOSS Needle shows that the sequence of 2WNC_AChBP has a closer identity and similarity to c_a7nACh (Id ¼ 27.4%; Sim ¼ 41.8%) than to h_5HT3
(Id ¼ 19.4%; Sim ¼ 31.8%) (Rice et al., 2000). To facilitate comparisons with previous work, the numbering used throughout this manuscript refers to residues at equivalent positions
of the mouse 5-HT3A subunit (Q6J1J7).
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orientations of several 5-HT3 receptor ligands, but all of these have
been performed on a close structural homologue rather than the
native receptor. For example, cocaine (pdbid: 2PGZ) and tropisetron
(2WNC) were crystallised in the binding site of acetylcholine
binding protein (AChBP), while granisetron (2YME) was crystallised
with an AChBP mutant containing two loop D amino acidssubstitutions that increased its afﬁnity for this ligand (Hansen and
Taylor, 2007; Hibbs et al., 2009; Kesters et al., 2013). Other studies
have sought to explore the binding orientation of granisetron using
homology modelling and ligand docking, but the majority of these
are over a decade old and do not beneﬁt from our improved un-
derstanding of the receptor family or developments in the com-
puter software used to model them (reviewed in Thompson et al.,
M.-D. Ruepp et al. / Neuropharmacology 119 (2017) 48e61502010). For example, the apo crystal structure of the mouse 5-HT3
receptor was published in 2014 and has provided an unprecedented
insight into the native structure in the absence of a ligand (Hassaine
et al., 2014).
In addition to high afﬁnity competitive antagonism at 5-HT3
receptors, tropisetron is also reported to bind to the a7 nACh re-
ceptor which belongs to the same Cys-loop receptor family (Macor
et al., 2001; Papke et al., 2005). However, at a7 nACh receptors
tropisetron causes activation. In contrast, at the same receptor,
binding of the very close granisetron congener and 5-HT3 receptor
antagonist LY-278,584 cannot be detected (Macor et al., 2001).
Despite these pharmacological differences, in co-crystal structures
with the homologue AChBP, tropisetron and granisetron adopt
almost identical positions and orientations in the binding site.
Given the quite distinct pharmacological properties of these ligands
it is therefore unclear whether the structures are true representa-
tions of the orientations found at 5-HT3 or a7 nACh receptors, and if
they are, which of the two receptors the AChBP co-crystal struc-
tures most closely resemble.
Here we probe the binding orientations of tropisetron and
granisetron at 5-HT3 receptors, using a combination of bioinfor-
matics, cysteinemutagenesis and the synthesis of ligand analogues.
The results show that their orientations differ, and question
whether it is appropriate to use these receptor homologues for
predicting ligand binding at different members of the Cys-loop
family (Thompson et al., 2017).
2. Results
2.1. Docking
To gain insights into potential binding-site interactions, residues
located within 5 Å of tropisetron or granisetron were identiﬁed
from four sources; (1) tropisetron in the AChBP co-crystal structure
2WNC, (2) granisetron in the AChBP co-crystal structure 2YME, (3)
in silico docking of tropisetron into a 5-HT3 receptor homology
model based upon 2WNC, and (4) in silico docking of tropisetron
into 2YME (Fig. 2). From the analysis of the resultant 22 ligand
orientations, a total of 33 residue positions were identiﬁed as being
within 5 Å of a ligand, and were located throughout the binding
loops A - E (Table 1, Fig. 1). Five of the residues were common to all
predicted ligand orientations (W90, N128, W183, Y234, Y153).
Sixteen other residues (K112, I127, E129, Y141, V142, Y143, V150,
N152, K154, P155, T179, F180, T181, H185, A235, E236) were unique
to only one of the four predictions (Table 1). The remaining 12
residues (D69, I71, R92, Q151, L126, S182, L184, M228, E229, S230,
S231, N232) were distributed in at least two of the predictions. Of
the 33 identiﬁed residues, 23 were mutated to cysteine.
2.2. Radioligand binding
Untransfected HEK293 cells showed no saturable binding with
[3H]tropisetron or [3H]granisetron, but upon transient expression
of wild type 5-HT3 receptors both ligands displayed high-afﬁnity
saturable binding (Tables 2 and 3). Non-speciﬁc binding was
30.3 ± 1.8% (n ¼ 8) of total for tropisetron and 6.7 ± 0.4% (n ¼ 6) for
granisetron. Kd values were similar to those reported elsewhere
(Neijt et al., 1988; Thompson et al., 2005).
2.3. Effects of mutations on tropisetron binding
The binding afﬁnity of [3H]tropisetron at each of the mutant
receptors is shown in Table 2 and their locations in the 5-HT3 re-
ceptor binding site in Fig. 3. Changing 7 of the 23 residues caused
no signiﬁcant change in afﬁnity when compared to wild typereceptors, suggesting they do not have a signiﬁcant role in ligand
binding or the structure of the binding site (I71, Q151, T179, L184,
S230, S231, N232). For the remaining 16 mutants there were dif-
ferences in the binding afﬁnities, indicating that these residuesmay
interact with the ligand or alter the receptor structure. Of these, 9
had reduced afﬁnities (R92, L126, N128, Y153, P155, T181, M228,
E229, E236) and 7 showed no saturable binding (Kd > 20 nM; D69,
W90, E129, Y143, W183, H185, Y234).
2.4. Effects of mutations on granisetron binding
Crystal structures of tropisetron or granisetron bound to the
homologue AChBP (Fig. 2C) reveal very similar ligand orientations
(Hibbs et al., 2009; Kesters et al., 2013). To determine whether
these two ligands also adopt such similar poses in the 5-HT3 re-
ceptor we performed saturation binding with radiolabelled grani-
setron on the same mutants used for the tropisetron study. Of the
23 substitutions, 8 similarly affected granisetron binding, while the
remaining 15 showed differing effects for the two ligands (Table 3,
Fig. 3). Of those that were similar, the substitutions W90C, E129C
and W183C abolished binding, Y153C reduced the afﬁnity, and
Q151C, L184C, S231C and N232C had no effect. In contrast to tro-
pisetron, saturable binding of granisetron could be detected with
D69C, Y143C and H185C, the mutants I71C, T179C and Y234C
showed a signiﬁcant decrease in afﬁnity, S230C increased the af-
ﬁnity, R92C and T181C did not show saturable binding, and binding
was unaltered by substitutions L126C, N128C, P155C, M228C,
E229C, and E236C.
2.5. Western blot of non-binding mutants
Three of the mutant receptors did not bind [3H]tropisetron or
[3H]granisetron (W90C, E129C, W183C). To conﬁrm that these re-
ceptors were expressed we performed Western blot with a 5-HT3
receptor-speciﬁc antibody. No immunostaining was apparent from
untransfected HEK 293 cells, but clear bands were seen for wild
type and mutant receptors at the expected size (Fig. 4).
2.6. Binding of granisetron & tropisetron derivatives
In addition to the changes made to the receptor, tropisetron and
granisetron were also altered by synthesising derivatives (Table 4).
It was clear from the afﬁnities of these derivatives that modiﬁcation
of the bicyclic amine (N-80) position was poorly tolerated by tro-
pisetron, while substitution at the corresponding nitrogen of gra-
nisetron (N-9’) was less detrimental (see Table 4 for atom
numbering). At the opposite end of the molecule, modiﬁcations at
each of the three positions (C-5, C-6 and C-7) within the hetero-
aromatic ring of tropisetron reduced the binding afﬁnity by 253-
fold or less, while modiﬁcation of only the C-5 position in grani-
setron caused a >10,000-fold decrease in afﬁnity. These structure-
activity relationships (SAR) of tropisetron and granisetron show
that the two structurally similar ligands have different substitution
tolerance patterns with respect to 5-HT3 receptor binding.
2.7. Binding at a7 nACh receptors
In contrast to its antagonist actions at 5-HT3 receptors, tropi-
setron is a partial agonist at a7 nACh receptors (Macor et al., 2001;
Papke et al., 2005). A comparative study of its binding at these two
receptor types could therefore provide insights into these distinct
properties. However, saturation binding of [3H]tropisetron and [3H]
granisetron could not be detected at a7 nACh receptors. In contrast,
[3H]epibatidine bound with high afﬁnity (Kd ¼ 8.81 ± 0.13 nM,
n ¼ 5), allowing the afﬁnities of non-radiolabelled tropisetron and
Fig. 2. Binding of tropisetron. Predicted binding clusters for tropisetron docked into (A) a homology model of the 5-HT3 receptor binding site based upon the template 2WNC
(Model-1), and (B) the crystal structure 2YME (Model-2). (C) Co-crystal structures 2WNC and 2YME show AChBP bound with tropisetron and granisetron respectively. In panels 2A &
2B all 10 predicted ligand poses are overlaid. 5-HT3 receptor residues within 5 Å of tropisetron in each of these poses are shown in Table 1.
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this gave a Ki of 1.58 ± 0.84 mM (n ¼ 3), while competition was not
detected for granisetron at a concentration of up to 100 mM.3. Discussion
Tropisetron and granisetron showed high-afﬁnity, saturable
binding at 5-HT3 receptors. For the majority (15/23) of cysteine
substitutions we made to this receptor, the effects on binding were
different for the two ligands, suggesting they may adopt different
orientations. This observation was supported by our SAR on ana-
logues of the same ligands, but conﬂicts with the very similar poses
seen in co-crystal structures of these ligands bound to AChBP.
There have been several studies characterising the binding of
orthosteric ligands at 5-HT3 receptors and a consensus regarding
their function has been further guided by themore recentmouse 5-
HT3 crystal structure 4PIR (Hassaine et al., 2014; Thompson et al.,
2010). Some residues are thought to interact with the ligands, but
others are thought to have primarily structural roles. From the
crystal structure 4PIR it is clear that a hydrogen bond between E129
and T179 is structural (Hassaine et al., 2014). Such an interaction is
supported by our ﬁnding that E129C abolishes binding of both li-
gands and by other reports that describe similar effects ongranisetron, GR65630 and VUF10166 (Boess et al., 1997; Price et al.,
2008; Thompson et al., 2005, 2014). For T179C the effects on the
two ligands were not as pronounced, but as both threonine and
cysteine can act as hydrogen bond donors this property may be
retained following substitution; consistent with this, substitution
to serine also preserves granisetron binding (Thompson et al.,
2005). L184 and H185 are also thought to make structural contri-
butions by forming, respectively, hydrophobic interactions and a
network of hydrogen bonds (Hassaine et al., 2014; Thompson et al.,
2008). For L184 the absence of effects for both ligands were similar
to previous reports of isoleucine substitution on granisetron
binding, and as the sulphur in cysteine has a similar hydrophobic
character to the side chains of leucine and isoleucine our result was
anticipated (Nagano et al., 1999; Thompson et al., 2008). For H185 a
substitution to cysteine would also conserve its side-chain in-
teractions as both residues are capable of hydrogen bonding.
However, it was previously reported that mutations at this location
reduce cell-surface expression, and the lower Bmax value we
measured for granisetron (H185C ¼ 123 ± 23 fmol mg1; wild
type ¼ 4843 ± 512 fmol mg1; paired samples, n ¼ 4) is consistent
with this (Joshi et al., 2006; Thompson et al., 2008). For tropisetron
it is therefore possible that the absence of binding does not reveal
interactions but, given the higher levels of non-speciﬁc binding,
Table 1
Residues predicted to be within 5 Å of tropisetron or granisetron in the 5-HT3A receptor binding site.
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Table 2
Saturation binding of [3H]tropisetron at 5-HT3A receptor cysteine mutants.
Loop Mutant pKd(± SEM) n
Kd
(nM)
pKd (WT) –pKd(mut)
Wild type 9.15 ± 0.06 8 0.72
D69C NB* 5 -  
I71C 8.87 ± 0.08 8 1.36
W90C NB* 8 -  
R92C 8.74 ± 0.04* 7 1.82
L126C 8.75 ± 0.10* 6 1.79
N128C 8.14 ± 0.04* 6 7.28
E129C NB* 9 -  
Y143C NB* 7 -  
Q151C 8.95 ± 0.04 8 1.11
Y153C 8.70 ± 0.07* 7 1.99
P155C 8.44 ± 0.16* 5 3.60
T179C 8.86 ± 0.08 5 1.38
T181C 8.23 ± 0.09* 7 5.85
W183C NB* 7 -  
L184C 8.85 ± 0.11 7 1.41
H185C NB* 7 -  
M228C 8.69 ± 0.07* 5 2.04
E229C 8.35 ± 0.11* 6 4.51
S230C 9.43 ± 0.03 5 0.37
S231C 8.92 ± 0.16 6 1.20
N232C 9.02 ± 0.11 5 0.96
Y234C NB* 5 -  
E236C 8.30 ± 0.08* 6 5.03
D
A
E
B
C
1-1 0
* signiﬁcantly different (1-way ANOVA and a Dunnett's Post-Test) to wild type receptors. SED ¼ standard error of the difference.
M.-D. Ruepp et al. / Neuropharmacology 119 (2017) 48e61 53instead reveals expression levels that are below the threshold for
detection.
In contrast to the structural roles described above, other binding
site residues are thought to be responsible for direct ligand in-
teractions. For some of these, the changes in afﬁnity were large and
provided compelling evidence of an interaction, particularly where
the effects on tropisetron and granisetron differed. For example, the
loop B mutant T181C caused a 6-fold decrease in afﬁnity for tro-
pisetron, but abolished granisetron binding. As 4PIR shows that this
residue faces into the binding pocket, and mutations to smaller
side-chains (Ala or Ser) are known to have no effect on granisetron
binding, this difference may result from steric constraints that
affect the two ligands differently (Thompson et al., 2008, 2011,
2014). In loop A, N128 also points towards the binding site, but
consistent with the absence of speciﬁc interactions with the
equivalent residue in 2YME (Y91), the afﬁnity of granisetron was
not altered. In previous work, a similar absence of effects on gra-
nisetron has also been reported for range of other substitutions at
this location (Price et al., 2008; Sullivan et al., 2006). However, theeffects of N128C wemeasured on the afﬁnity of tropisetron (7-fold)
and previous reports of changes to the EC50 of 5-HT,mCPBG and the
binding afﬁnity of VUF10166 suggests that effects may depend
upon the ligand studied (Price et al., 2008; Sullivan et al., 2006;
Thompson et al., 2014). In P4IR, N128 lies close to L126 on loop A,
and E236 in loop C, none of which caused signiﬁcant effects on
granisetron binding. In contrast, tropisetron binding was altered by
mutation at all of these locations (7-, 2.5- & 10-fold respectively,
Table 2). When considered together this suggests that of the two
ligands studied only tropisetron extends into this region of the
binding pocket. Notably, neither L126 nor E236 are identiﬁed as
lying within 5 Å of tropisetron in the tropisetron co-crystal struc-
ture 2WNC (Table 1). In contrast, both residues are predicted to lie
within 5 Å of tropisetron in Cluster-A, suggesting that our muta-
genesis is more consistent with this predicted orientation (Figs. 3
and 5).
In loop D, R92C abolishes granisetron binding, but the afﬁnity
for tropisetron is reduced by only 2.5-fold. In the structure 2YME
the equivalent residue (R55) makes a cation-p interaction with
Table 3
Saturation binding of [3H]granisetron at 5-HT3A receptor cysteine mutants.
Loop Mutant pKd(± SEM) n
Kd
(nM)
pKd (WT) –pKd(mut)
Wild type 9.33 ± 0.11 6 0.46
D69C 9.51 ± 0.07 5 0.31
I71C 8.81 ± 0.17* 4 1.57
W90C NB* 5 -  
R92C NB* 8 -  
L126C 9.22 ± 0.18 4 0.60
N128C 9.53 ± 0.10 5 0.29
E129C NB* 4 -  
Y143C 9.42 ± 0.15 5 0.38
Q151C 9.32 ± 0.08 4 0.48
Y153C 8.84 ± 0.02* 6 1.43
P155C 9.29 ±0.02 3 0.51
T179C 8.92 ±.10* 4 1.21
T181C NB* 5 -  
W183C NB* 8 -  
L184C 9.55 ± 0.03 3 0.28
H185C 9.43 ± 0.09 3 0.37
M228C 9.34 ± 0.05 3 0.46
E229C 9.31 ± 0.04 3 0.49
S230C 9.84 ± 0.08* 3 0.15
S231C 9.63 ± 0.13 6 0.24
N232C 9.53 ± 0.09 4 0.30
Y234C 8.26 ± 0.15* 4 5.51
E236C 9.09 ± 0.09 3 0.82
D
A
E
B
C
1-1 0
* signiﬁcantly different (1-way ANOVA and a Dunnett's Post-Test) to wild type receptors. SED ¼ standard error of the difference.
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report here and by previous ﬁndings that showed preserving the
charge in R92K mutants does not affect granisetron binding (Duffy
et al., 2012; Kesters et al., 2013; Thompson et al., 2005). In sharp
contrast, the much smaller change in afﬁnity shown by tropisetron
suggest that interactions at R92 are less important. In loop E, sub-
stitution of the aromatic residue Y143C abolished tropisetron
binding, but did not affect the binding of granisetron. In the AChBP
crystal structures 2YME and 2WNC, neither of the ligands extends
towards this residue and an effect would not be anticipated (Fig. 2).
For granisetron the absence of an effect is consistent with the
crystallographic evidence, but for tropisetron it is not. Instead, our
results are more consistent with the in silico predictions found in
Cluster-A (Fig. 5), where tropisetron extends towards Y143, but
is > 5 Å from R92. Indeed, the orientation of tropisetron in the
crystal structure 2WNC might be considered atypical as other a7nACh agonists such as nicotine (1UW6), varenicline (4AFT) and
acetylcholine (3WIP) also display low afﬁnity binding at 5-HT3 re-
ceptors and extend towards this region of the binding site. D69C
also abolished tropisetron binding, but did not alter the binding
afﬁnity of granisetron. However, D69 lies outside of the recognised
binding loops and, although it was identiﬁed as lying within 5 Å of
tropisetron in a limited number of the docked poses, it does not
have an obvious role in our 5-HT3 receptor homologymodels or the
AChBP crystal structures. A more likely explanation is that, similar
to H185C, the poor expression levels revealed by granisetron
(D69C ¼ 119 ± 16 fmol mg1; wild type ¼ 4843 ± 512 fmol mg1;
paired samples, n ¼ 4) may be below the detection threshold for
tropisetron.
Other mutations abolished the binding of both ligands. For
example, the effect of the aromatic loop B residue W183C was
anticipated for both tropisetron and granisetron as it is centrally
Fig. 3. Binding site residues and the corresponding change in afﬁnity when they are
mutated. All positions in this ﬁgure are shown as cysteine and are colour coded ac-
cording to the extent of the change in afﬁnity this mutation caused. Residues that are
thought to have a structural role have been omitted. The structure isModel-1, and more
details of the effects of these cysteine substitutions can be found in Tables 2 and 3.
Fig. 4. Expression of mutant 5-HT3 receptors. Three of the mutant receptors did not
bind either [3H]tropisetron or [3H]granisetron (W90C, E129C, W183C). To conﬁrm that
this could be attributed to altered binding rather than changes in expression, these
mutants were probed by Western blot using a 5-HT3 receptor-speciﬁc antibody.
Expression of the mutants and wild type receptors were comparable, and there was no
detection in untransfected cells. In each lane 105 cell equivalents were loaded and an
antibody against the cleavage and polyadenylation speciﬁcity factor (CPSF) included as
an internal control. Note that whole-cell homogenates were used for both radioligand
binding and Western blot to enable monitoring of the same populations of both
intracellular and cell-surface receptors.
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several other 5-HT3 receptor ligands (Thompson et al., 2010). In
loop C, Y234 also contributes to the aromatic nature of the binding
site, and our ﬁnding that tropisetron binding was abolished and the
afﬁnity of granisetron was reduced (12-fold) is consistent withreports that aromatic properties at this position are important
(Beene et al., 2004). In all of the models and the AChBP crystal
structures presented here, the aromatic residue Y234, or its
equivalent (Y193), interacts with tropisetron and granisetron
(Kesters et al., 2013). As a similar side chain orientation is seen in
4PIR, ligand interactions with this residue are also likely in the 5-
HT3 receptor binding site and are supported by the large effects
we see for both ligands (Kesters et al., 2013). Substitution of another
aromatic residue, W90 in loop D, also abolished the binding of both
tropisetron and granisetron, similar to reports for other 5-HT3 re-
ceptor ligands (Thompson et al., 2014; Venkataraman et al., 2002;
Yan et al., 1999). Again, the aromatic character of W90 is impor-
tant as removal of the aromatic ring (W90A, W90S) eliminates
granisetron binding, but conservative substitutions (W90Y) have
reduced effects (Price and Lummis, 2004; Spier and Lummis, 2000;
Thompson et al., 2005; Yan and White, 2005). In contrast to the
residues described above, I71C lies outside of the recognised
binding loops but is found within 5 Å of tropisetron in a limited
number of the docked poses and 2WNC, and within 5 Å of grani-
setron in 2YME (Table 1). Nevertheless, there are no obvious ligand
interactions predicted with this residue in our models or the crystal
structures and the similar changes in afﬁnity seen for both ligands
(1.9 & 3.4-fold) may reveal a non-speciﬁc effect. P155 also lies
outside of the recognised binding loops, but might be anticipated to
impact binding as prolines often distort protein backbones. It is not
clear from the structural evidence why the afﬁnity of granisetron
was unaffected and tropisetron showed a 5-fold decrease, but it is
possible that by distorting the backbone the positions and side-
chain orientations of the other interacting residues are affected.
When residues that signiﬁcantly affected tropisetron binding
were compared to the residues predicted to lie within 5 Å of this
ligand, the docked poses inModel-1were the most consistent with
the pattern of changes we observed. For example, residues L126
(loop A), T181, H185 (B), E236 (C) and Y143 (E) signiﬁcantly altered
the afﬁnity for tropisetron and were also predicted in Model-1,
while none of these were identiﬁed in either 2WNC or the poses
predicted by docking tropisetron into 2YME (Table 1). Docked poses
inModel-1 fell into 3 main clusters, and Cluster-Awas the largest of
these (Fig. 5). This cluster contained the most residues that affected
binding and was the only cluster to predict that tropisetron extends
towards Y143, a loop E substitution that abolished tropisetron
binding. This cluster also correctly excluded residues I71 and S231
which caused little or no change when substituted (Table 2, Fig. 3).
Although 4 other residues (T179, L184, Q151, S230) were identiﬁed
as being within the 5 Å docking sphere of Cluster-A but had no
effects on binding, none of these were predicted to directly interact
with tropisetron; T179 and L184 are likely to have a structural role
(discussed above), the side chain of S230 is predicted to form a
hydrogen-bond with the indole NH of tropisetron that would be
retained with a cysteine substitution, and Q151 does not make
speciﬁc interactions with the ligand. Furthermore, in Cluster-A, the
bicyclic tropane moiety of tropisetron is located close to W183,
consistent with the cation-p interaction that unnatural amino acid
mutagenesis has identiﬁed for both granisetron and ondansetron at
this location (Duffy et al., 2012). As related molecules that contain a
similar moiety also inhibit the 5-HT3 receptor, such as tropine and
atropine, retention of this interaction also seems quite likely for
tropisetron (Lochner and Thompson, 2016; Papke et al., 2005). Our
mutagenesis is therefore most consistent with the position of tro-
pisetron predicted by Cluster-A; although we stress that its exact
orientationmay differ to that shown as our docking could be biased
by the modelling template.
In contrast to tropisetron, the residues that affected granisetron
binding were more limited in number and many were located at
different positions (Fig. 3). Comparing the residues that affected
Table 4
Afﬁnities determined from binding tropisetron, granisetron and their analogues.
Compound R R0 pKi Mean ± SEM Ki (nM) n Fold change
Tropisetron Derivatives
Parent Scaffold H CH3 9.15 ± 0.06 0.72 8 e
1 5-OMe CH3 7.02 ± 0.03 95.5 4 133
2 6-OMe CH3 6.74 ± 0.04 182 4 253
3 7-OMe CH3 7.52 ± 0.12 30.2 4 42
4 H Bn 5.84 ± 0.20 1445 6 2007
Granisetron Derivatives
Parent Scaffold H CH3 9.33 ± 0.11 0.47 6 e
5 5-OMe CH3 5.27 ± 0.02 5370 4 >10,000
6 6-OMe CH3 6.35 ± 0.18 447 5 951
7 7-OMe CH3 6.92 ± 0.24 120 7 255
8 H Bn 6.72 ± 0.24 190 6 404
* The structures below show tropisetron and granisetron with example saturations binding curves.
M.-D. Ruepp et al. / Neuropharmacology 119 (2017) 48e6156binding with those predicted to interact with the ligand it is clear
that the position of granisetron in 2YME ismore consistent with the
locations of the substitutions that altered its binding afﬁnity. For
example, of the 9 residues identiﬁed as being within 5 Å of grani-
setron in 2YME (Table 1), 6 of these (I71, W90, R92, Y153, W183,
Y234) signiﬁcantly reduced the afﬁnity of granisetron (Table 3).
Further, another 10 residues that are not within 5 Å of granisetron
in 2YME also had no effect on binding (D69, L126, Y143, P155, L184,
H185, M228, E229, N232, E236). For granisetron, we suggest that
the position of the ligand in 2YME is broadly consistent with our 5-
HT3 receptor mutagenesis.
By synthesising tropisetron and granisetron derivatives wewere
also able to probe binding by ligand SAR. Tropisetron was more
tolerant to aromatic substitutions at the C-5, C-6, C-7 indole pos-
itons, while incorporation of a benzyl group to the N-80 position atthe opposite end of the ligand was less tolerated (Table 4). This SAR
is most consistent with the predicted orientation for tropisetron
found in Cluster-A as the benzyl substituent lies in a sterically un-
restricted region (Fig. 5). Further, in the co-crystal structure 2W8G,
Ulens et al. (2009) describes a comparable orientation for cmp-35, a
ligand that similarly contains a tropane bicycle conjugated to a
benzyl ring. For granisetron, our results are consistent with reports
showing that conjugation of a methoxy group to the C-5 position of
granisetron is not permitted, but increased tolerance is seen as we
move towards the C-7 position and the indazole N-1 (Vernekar
et al., 2010). In 2YME the C-7 and indazole N-1 nitrogen of grani-
setron lies within a sterically unrestricted location (Figs. 2C and 5)
and we have previously noted that attachment of bulky ﬂuo-
rophores via long linkers to each position can be accommodated
(Jack et al., 2015; Simonin et al., 2012). These results contrast with
Fig. 5. The three docked-pose clusters predicted by docking tropisetron into a homology model of the 5-HT3 receptor that was based on the template 2WNC (Model-1). Repre-
sentative orientations of tropisetron are shown for each of the clusters A, B and C (for an overlay of all docked poses see Fig. 2A). In panel 5D, tropisetron (Cluster-A, pink) , and
granisetron (2YME, green) are overlaid. The residues shown are those that abolished binding in Fig. 3 (Cluster-A, red; 2YME, cyan). Other residues are omitted for clarity. For a full list
of the identiﬁed residues in Cluster-A and 2YME see Table 1. The docked-pose predicted in Cluster-A is the most consistent with the binding results presented here. (For inter-
pretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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the orientation in the crystal structure 2YME. However, this
orientation of granisetron is harder to reconcile with the ﬁnding
that a benzyl group on the sterically restricted azabicyic ring of
granisetron is better tolerated than elaborations of the relatively
unrestricted C-5 position. We therefore speculate that N-9’-benzyl
granisetron adopts a different orientation to the parent ligand;
indeed, our in silico docking suggests that the addition of the benzyl
ring to granisetron could force it to adopt an orientation similar to
that of the benzyl derivative of tropisetron (cmp-35) described
above (data not shown). In summary, these results show that tro-
pisetron and granisetron have quite distinct SAR and further sup-
port our proposal that these two ligands are orientated differently
in the 5-HT3 receptor binding site.
Originally we had sought to probe the different orientations of
tropisetron at 5-HT3 and a7 nACh receptors and gain insights into
its distinct actions at these two receptor types. However, saturation
binding of tropisetronwas undetectable at a7 nACh receptors, and a
low binding afﬁnity (1.58 mM) was only revealed followingcompetition with [3H]epibatidine. This low afﬁnity is in contrast to
the ﬁndings of Macor et al. (2001) who reported a Ki of 6.9 nM at a7
nACh receptors, but is closer to the value that might be expected for
a low potency agonist (e.g. EC50¼ 1.3 mM,Macor et al., 2001; 0.6 mM,
Papke et al., 2005), and to the afﬁnity (0.5 mM) that was measured
for tropisetron at AChBP and then used for co-crystallisation (Hibbs
et al., 2009). Currently there are no mutation studies to support
speciﬁc binding-site interactions between tropisetron and a7 nACh
receptors. However, the amino acid sequences of AChBP and a7
nACh receptors share much stronger amino acid conservation with
each other than with the 5-HT3 receptor and it might be expected
that their binding afﬁnities would also be closer (Fig. 1). In contrast,
of the key 5-HT3 receptor residues identiﬁed for tropisetron in our
study, N128 (Tyr in 2WNC and a7nACh), Y143 (Val in 2WNC; Leu in
a7 nACh) andMESSN in loop C (CCPEP in 2WNC; CCKEP in a7 nACh)
are quite different to their equivalents in 2WNC and the a7 nACh
receptor, and may account for the much higher afﬁnity of 5-HT3
receptors when compared to the other two proteins. Indeed, the
amino acid conservation and similar afﬁnities at AChBP and the
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the binding orientation of tropisetron at the a7 nACh. For grani-
setron, AChBP and the a7 nACh receptor are less similar as this
ligand has a Kd of 1 mM at AChBP (Kesters et al., 2013), whilst we
found no detectable binding at a7 nACh receptors with concen-
trations of up to 30 mM. Several of the residues in loops A, C and D
are potential candidates for this difference as these they make
contact with granisetron and differ between all three receptors. In
particular, the residues of loop D (YIWYRQY in 5-HT3; NIWLQMY IN
a7 nACh; VYYEQQR IN 2WNC) are highly varied, and in the 5-HT3
receptor this loop makes direct contact with granisetron (R92
forms a cation-p interaction) but not with tropisetron. However, it
must be stressed that these speculations require experimental
support and in future substituting AChBP and 5-HT3 residues into
the a7 nACh receptor in an attempt to recover the higher afﬁnities
might provide clues as to which are important.
Our results conﬁrm that both tropisetron and granisetron
interact with residues in the 5-HT3 receptor orthosteric binding
site, but mutagenesis and SAR with synthetic derivatives show that
they are likely to adopt distinct poses when they are bound. These
results contrast with the almost identical orientations seen in co-
crystal structures of these ligands bound to the structurally-
related protein AChBP. Ligand-based virtual screening has become
a popular tool to discover novel active compounds to modulate
therapeutically interesting protein targets (Reymond et al., 2011).
These approaches are based on the assumption that structurally
similar molecules should exhibit similar binding interactions with
the target protein and hence display the same biological activities
(Thompson et al., 2017). Our study suggests that even the very close
structural similarity between tropisetron and granisetron does not
necessarily lead to the same binding orientation. In addition, AChBP
is sometimes used as amodel for differentmembers of the Cys-loop
family, but our results suggest caution may be needed when
interpreting ligand orientations in these different receptor
homologues.
4. Materials and methods
4.1. Radioligands
[3H]Tropisetron was synthesized (Metis Laboratories Inc, NY,
USA) from its desmethyl analogue (0.5 mg) in a tritiomethylation
reaction by heating at 80 C for 2 h with 50 mCi [3H]methyl iodide
in tetrahydrofuran (THF) (0.4 ml). After evaporation of the THF the
residue was subjected to reversed phase chromatography (Kro-
masil 100 C18, 7 mm, 250  10 mm, 2 mL min1) using 31% ACN in
0.1% TFA as eluent. The eluent was stripped off and the residue was
dissolved in 12 mL absolute ethanol. The [3H]tropisetron had a
speciﬁc activity of 73.5 Ci/mmol and radiochemical purity of >99%.
[3H]granisetron (63.5 Ci/mmol) and [3H]epibatidine (55.8 Ci/mmol)
were purchased from Perkin Elmer (Waltham, MA) and were >97%
chemical purity.
4.2. Synthesis of analogues
All reactions were performed under an inert argon atmosphere.
Anhydrous THF and CH2Cl2 were obtained by ﬁltration through a
system of alumina columns under a positive pressure of argon.
Solvents were evaporated under reduced pressure at approxi-
mately 45 C using a Büchi Rotavapor or under high vacuum on a
Schlenk line. Reagents and solvents were purchased from Sigma-
Aldrich, Acros, Alfa Aesar, Fischer Scientiﬁc or H€anseler and used
without further puriﬁcation. Reactions were monitored by thin
layer chromatography (TLC) using aluminum sheets pre-coated
with silica gel (Macherey-Nagel ALUGRAM Xtra SII, G/UV254).Detection was achieved by excitation with a UV light source (lmax
254 nm) or by staining with vanillin spray, with subsequent heat-
ing. Flash column chromatography was carried out using silica gel
from Sigma-Aldrich (pore size 60 Å, 230e400mesh particle size) as
the stationary phase. 1H and 13C NMR spectra were recorded at 300
and 400MHz, and 75 and 100MHz respectively, on a Bruker Avance
300 and Avance II 400. Chemical shifts are reported in d (ppm) and
are referenced to the residual solvent peak. The order of citation in
parentheses is (1) multiplicity: s (singlet), d (doublet), t (triplet), m
(multiplet) etc., (2) coupling constants (J) in Hz, (3) number of
equivalent nuclei (by integration), and (4) assignment. Mass spectra
and high resolution mass spectra (HRMS) were recorded on a
ThermoScientiﬁc LTQ Orbitrap XL spectrometer consisting of a
linear ion trap (LTQ) featuring a HCD collision cell, coupled to the
Orbitrap mass analyzer, equipped with a nanoelectrospray ion
source (NSI). MS and HRMS spectra were determined by the Mass
Spectrometry Group at the Department of Chemistry and
Biochemistry, University of Bern (PD Dr. S. Schürch). The purity of
the compounds was determined by UPLC-MS on a Dionex Ultimate
3000 using a reversed-phase column Dionex Acclain RSLC, 120C18,
3  50 mm, 2.2 mm, 120 Å pore size, ﬂow 1.2 mL/min. Following
gradient was used: 30 s at 100% A, then 100% A to 100% D over 5min
(A ¼ 100% H2O with 0.1% TFA, D ¼ H2O/MeCN 10:90 with 0.1% TFA).
Purity was determined by total absorbance at 214 nm.
The synthesis of substituted granisetron derivatives has been
described previously (Vernekar et al., 2010). The synthesis of
substituted tropisetron derivatives was achieved by following this
general procedure: the corresponding indole-3-carboxylic acid (1
equiv.) was suspended in CH2Cl2. An excess of thionyl chloride was
added and reﬂuxed for 2 h under an argon atmosphere. After
completion, the volatiles were removed and the solid co-
evaporated with CH2Cl2. The solid was dried and used in the next
step without puriﬁcation. In a separate ﬂask the tropine (1-2 equiv.)
was dissolved in THF under argon and cooled to 0 C. n-Butyl-
lithium solution (2.5 M in hexanes) was added and the resulting
solution was stirred for 30 min at 0 C. The acid chloride inter-
mediate previously preparedwas dissolved in THF and added to the
pre-cooled solution. The resulting mixture was stirred at 0 C for
1 h and at room temperature overnight. MeOH was added and the
solvents were removed under reduced pressure. The residue was
dissolved in CH2Cl2, washed with water and dried over Na2SO4.
After ﬁltration the organic phase was evaporated under reduced
pressure. The crude was puriﬁed by column chromatography.
5-Methoxy-tropisetron ((1R,3r,5S)-8-methyl-8-azabicyclo[3.2.1]
octan-3-yl 5-methoxy-1H-indole-3-carboxylate) was synthesized
according to the general procedure, using 5-methoxy-1H-indole-3-
carboxylic acid (50 mg, 0.26 mmol), thionyl chloride (0.5 mL,
6.9 mmol, 26 equiv.), tropine (73 mg, 0.52 mmol, 2 equiv.) and n-
butyllithium solution (2 equiv.). After puriﬁcation by column
chromatography (silica gel, CH2Cl2/MeOH 8:2 þ 0.5% aq NH3), 5-
methoxy-tropisetron was obtained as a white solid (27 mg, 33%
yield). 1H NMR (DMSO-d6) d 1.76 (d, J ¼ 14.9, 2H, aliphatic-CH),
1.98e2.18 (m, 6H, aliphatic-CH), 2.25 (s, 3H, N-Me), 3.14 (br s, 2H,
aliphatic-CH), 3.78 (s, 3H, -OMe), 5.10 (t, J ¼ 5.1, 1H, -COO-CH-
(CH2)2), 6.84 (dd, J ¼ 2.5, J ¼ 8.8, 1H, C(6)-H), 7.39 (d, J ¼ 8.8, 1H,
C(7)-H), 7.51 (d, J¼ 2.5,1H, C(4)-H), 7.93 (d, J¼ 3.1,1H, C(2)-H),11.77
(s, 1H, NH). 1H NMR (CDCl3) d 1.88 (d, J ¼ 14.9, 2H, aliphatic-CH),
1.99e2.17 (m, 4H, aliphatic-CH), 2.23e2.35 (m, 2H, aliphatic-CH),
2.31 (s, 3H, N-Me), 3.19 (br s, 2H, aliphatic-CH), 3.80 (s, 3H,
-OMe), 5.23 (t, J ¼ 5.2, 1H, -COO-CH-(CH2)2), 6.84 (dd, J ¼ 2.5,
J ¼ 8.9, 1H, C(6)-H), 7.39 (d, J ¼ 8.2, 1H, C(7)-H), 7.64 (d, J ¼ 2.4, 1H,
C(4)-H), 7.74 (s,1H, C(2)-H), 9.60 (s,1H, NH). 13C NMR (CDCl3) d 25.9,
36.4, 40.1, 55.9, 60.2, 66.2, 102.4, 108.6, 112.6, 113.9, 126.9, 131.2,
131.3, 155.9, 164.7. HRMS (ESIþ): exact mass calcd for C18H23N2O3
[MþH]þ 315.1703, found 315.1707, D: 1.2 ppm. UHPLC (l ¼ 214 nm)
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6-Methoxy-tropisetron ((1R,3r,5S)-8-methyl-8-azabicyclo[3.2.1]
octan-3-yl 6-methoxy-1H-indole-3-carboxylate) was synthesized
according to the general procedure, using 6-methoxy-1H-indole-3-
carboxylic acid (35 mg, 0.183 mmol), thionyl chloride (0.3 mL,
4.14 mmol, 22 equiv.), tropine (52 mg, 0.366 mmol, 2 equiv.) and n-
butyllithium solution (2.05 equiv.). After puriﬁcation by column
chromatography (silica gel, CH2Cl2/MeOH 8:2þ 0.5% aq NH3), 6-
methoxy-tropisetron was obtained as a white solid (21 mg, 36%
yield). 1H NMR (DMSO-d6) d 1.78 (d, J¼ 14.9, 2H, aliphatic-CH), 2.04
(br s, 4H, aliphatic-CH), 2.08e2.19 (m, 2H, aliphatic-CH), 2.28 (s, 3H,
N-Me), 3.19 (br s, 2H, aliphatic-CH), 3.78 (s, 3H, -OMe), 5.07 (t,
J ¼ 4.9, 1H, -COO-CH-(CH2)2), 6.83 (dd, J ¼ 2.3, J ¼ 8.7, 1H, C(5)-H),
6.98 (d, J ¼ 2.2, 1H, C(7)-H), 7.86 (d, J ¼ 2.8, 1H, C(2)-H), 7.88 (d,
J ¼ 8.6, 1H, C(4)-H), 11.67 (s, 1H, NH). 1H NMR (CDCl3) d 1.91 (d,
J ¼ 14.8, 2H, aliphatic-CH), 2.05e2.15 (m, 4H, aliphatic-CH),
2.22e2.35 (m, 2H, aliphatic-CH), 2.34 (s, 3H, N-Me), 3.20 (br s,
2H, aliphatic-CH), 3.83 (s, 3H, -OMe), 5.26 (t, J ¼ 5.3, 1H, -COO-CH-
(CH2)2), 6.88 (d, J ¼ 2.1, 1H, C(7)-H), 6.93 (dd, J ¼ 2.3, J ¼ 8.7, 1H,
C(5)-H), 7.74 (s, 1H, C(2)-H), 8.09 (d, J ¼ 8.7, 1H, C(4)-H), 9.19 (s, 1H,
NH). 13C NMR (CDCl3) d 26.0, 36.6, 40.3, 55.8, 60.0, 66.5, 95.2, 109.3,
111.8, 120.3, 122.0, 130.0, 137.2, 157.2, 164.7. HRMS (ESIþ): exact
mass calcd for C18H23N2O3 [MþH]þ 315.1703, found 315.1701,
D: 0.6 ppm. UHPLC (l ¼ 214 nm) tR ¼ 2.19 min, 99% purity.
7-Methoxy-tropisetron ((1R,3r,5S)-8-methyl-8-azabicyclo[3.2.1]
octan-3-yl 7-methoxy-1H-indole-3-carboxylate) was synthesized
according to the general procedure, using 7-methoxy-1H-indole-3-
carboxylic acid (100 mg, 0.523 mmol), thionyl chloride (0.85 mL,
11.7mmol, 22 equiv.), tropine (81mg, 0.575mmol,1.1 equiv.) and n-
butyllithium solution (1.1 equiv.). After two puriﬁcations by column
chromatography (ﬁrst: Alox neutral, CHCl3/MeOH to 99:1; second:
silica gel, CH2Cl2/MeOH 8:2þ 0.5% aq NH3), 7-methoxy-tropisetron
was obtained as a white solid (19 mg, 12% yield). 1H NMR (DMSO-
d6) d 1.73 (d, J¼ 14.6, 2H, aliphatic-CH), 2.00 (br s, 4H, aliphatic-CH),
2.04e2.16 (m, 2H, aliphatic-CH), 2.21 (s, 3H, N-Me), 3.09 (br s, 2H,
aliphatic-CH), 3.94 (s, 3H, -OMe), 5.07 (t, J ¼ 5.1, 1H, -COO-CH-
(CH2)2), 6.78 (d, J ¼ 7.8, 1H, C(6)-H), 7.11 (t, J ¼ 7.9, 1H, C(5)-H), 7.62
(d, J¼ 8.0, 1H, C(4)-H), 7.79 (d, J¼ 3.0, 1H, C(2)-H), 12.07 (s, 1H, NH).
1H NMR (CDCl3) d 1.94 (d, J ¼ 14.9, 2H, aliphatic-CH), 2.03e2.21 (m,
4H, aliphatic-CH), 2.26e2.42 (m, 2H, aliphatic-CH), 2.37 (s, 3H, N-
Me), 3.24 (br s, 2H, aliphatic-CH), 3.96 (s, 3H, -OMe), 5.27 (t, J ¼ 5.2,
1H, -COO-CH-(CH2)2), 6.71 (d, J¼ 7.7, 1H, C(6)-H), 7.19 (t, J¼ 8.0, 1H,
C(5)-H), 7.78e7.83 (m, 2H, C(2)-H and C(4)-H), 9.32 (s, 1H, NH). 13C
NMR (CDCl3) d 25.9, 36.5, 40.2, 55.5, 60.2, 66.5, 103.1, 109.8, 113.9,
122.7, 126.9, 127.5, 130.2, 146.3, 164.6. HRMS (ESIþ): exact mass
calcd for C18H23N2O3 [MþH]þ 315.1703, found 315.1704, D: 0.3 ppm.
UHPLC (l ¼ 214 nm) tR ¼ 2.27 min, 91% purity.
N-80-Benzyl-tropisetron ((1R,3r,5S)-8-benzyl-8-azabicyclo
[3.2.1]octan-3-yl 1H-indole-3-carboxylate) was synthesized ac-
cording to the general procedure, using 1H-indole-3-carboxylic
acid (37 mg, 0.23 mmol), thionyl chloride (0.3 mL, 4.14 mmol, 18
equiv.), endo-8-benzyl-8-azabicyclo[3.2.1]octan-3-ol (50 mg,
0.23 mmol, 1 equiv.) and n-butyllithium solution (1.09 equiv.). After
puriﬁcation by column chromatography (silica gel, CH2Cl2/MeOH
95:5), N-80-Benzyl-tropisetron was obtained as a white solid
(18 mg, 22% yield). 1H NMR (DMSO-d6) d 1.77 (d, J ¼ 15.0, 2H,
aliphatic-CH), 2.04e2.20 (m, 6H, aliphatic-CH), 3.14 (br s, 2H,
aliphatic-CH), 3.55 (s, 2H, N-CH2-Ph), 5.16 (t, J ¼ 4.6, 1H, -COO-CH-
(CH2)2), 7.14e7.54 (m, 8H, Ar-H), 7.96e8.09 (m, 2H, Ar-H), 11.89 (s,
1H, NH). 1H NMR (CDCl3) d 1.86 (d, J ¼ 15.0, 2H, aliphatic-CH),
2.00e2.18 (m, 4H, aliphatic-CH), 2.30 (d, J ¼ 14.6, 2H, aliphatic-
CH), 3.23 (br s, 2H, aliphatic-CH), 3.59 (s, 2H, N-CH2-Ph), 5.25 (t,
J¼ 5.2,1H, -COO-CH-(CH2)2), 7.13e7.31 (m, 5H, Ar-H), 7.32e7.44 (m,
3H, Ar-H), 7.78 (d, J ¼ 2.9, 1H, C(2)-H), 8.10e8.22 (m, 1H, Ar-H), 8.93
(s,1H, NH). 13C NMR (CDCl3) d 26.2, 36.8, 56.6, 58.3, 67.1,109.3,111.8,117.6, 121.4, 122.2, 123.4, 126.1, 126.5, 128.6, 129.1, 130.9, 136.3,
164.5. HRMS (ESIþ): exact mass calcd for C23H25N2O2 [MþH]þ
361.1911, found 361.1911, D: 0.0 ppm. UHPLC (l ¼ 214 nm)
tR ¼ 2.59 min, 99% purity.
4.3. Site-directed mutagenesis
Mutagenesis was performed using the QuikChange method
(Agilent Technologies Inc., California, USA). Cysteine residues were
substituted for amino acids throughout each of the binding loops A
- E (Fig. 1). To facilitate comparisons with previous work, we have
used the numbering of the equivalent residues in the mouse 5-
HT3A subunit (Q6J1J7).
4.4. Cell culture and transfection
Human embryonic kidney (HEK) 293 cells were grown on
90 mm round tissue culture plates as monolayers in DMEM/F12
(Gibco, Life Technologies, CA, USA) supplemented with 10% fetal
bovine serum (FBS; Sigma Aldrich) at 37 C in a moist atmosphere
containing 5% CO2.
Human 5-HT3A subunit cDNA (Accession: P46098, kindly pro-
vided by J. Peters, Dundee University, UK) was cloned into
pcDNA3.1 for expression in HEK293 cells. The a7 nACh receptor was
a chimaera of the chick a7 nACh extracellular domain fused to the
5-HT3 transmembrane/intracellular domains as described by Eisele
et al. (1993) and was similarly cloned into pcDNA3.1. Cells were
transiently transfected with either of these cDNA constructs using
polyethyleneimine (PEI: 25 kDa, linear, powder, Polysciences Inc.,
Eppelheim, Germany). 30 ml of PEI (1 mg ml1), 5 mg cDNA and 1 ml
DMEMwere incubated for 10min at room temperature, added drop
wise to a 90 mm plate of 70e80% conﬂuent HEK293 cells, and
incubated for 2e3 days before use.
4.5. Radioligand binding
Transfected HEK 293 cells were scraped into 0.6 ml of ice-cold
10 mM HEPES buffer (pH 7.4) and frozen. After thawing, they
were washed with HEPES buffer, homogenised by trituration
through a 25 gauge (0.5 mm) needle, and 50 mg of cell suspension
incubated in 0.5 ml HEPES buffer containing different concentra-
tions of radioligand. Non-speciﬁc binding was determined using
100 mM granisetron (with [3H]tropisetron), 100 mM tropisetron
(with [3H]granisetron), or 30 mM -/-nicotine (with [3H]epibatidine).
Equilibrium reactions were incubated on ice for at least 1 h and
terminated by vacuum ﬁltration ontoWhatman GF/B ﬁlters wetted
with 0.3% polyethyleneimine, followed by two rapid washes with
2.5ml ice cold buffer. Radioactivity wasmeasured by scintillation in
Ultima Gold XR (Perkin Elmer, Waltham, MA) using a Tri-Carb
2100 TR (PerkinElmer) scintillation counter. Final counts were
monitored to ensure that binding never exceeded 10% of the added
concentrations of radioligands. For mutants that showed poor
expression (D69C, H185C), Bmax values were compared using paired
samples of wild type andmutant receptor prepared under identical
conditions on the same day.
Competition binding at a7 nACh receptors (10 point) was
determined by incubating preparations of HEK 293 cells transfected
with the a7 nACh receptor in 0.5 ml HEPES buffer containing 7 nM
[3H]epibatidine and differing concentrations of the competing li-
gands granisetron (maximal concentration used ¼ 30 mM) or tro-
pisetron (max ¼ 300 mM). Non-speciﬁc binding was determined
with 30 mM (-)/-nicotine. Equilibrium reactions were incubated on
ice for at least 1 h and bound radioligand measured using the same
method as described above.
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All data were analysed using GraphPad Prism v5. Individual
saturation binding experiments were ﬁtted to the equation below
and the ﬁtted values averaged to yield mean ± sem of n indepen-
dent experiments:
y ¼ Bmax  ½L KdKd þ ½L
where Bmax is maximum binding at equilibrium, Kd is the equilib-
rium dissociation constant and [L] is the free concentration of
radioligand. Afﬁnities were compared using 1-way ANOVA and a
Dunnett's Post-Test.
4.7. Detection
48 h post transfection, HEK293 cells were harvested in 10 ml
phosphate buffered saline (137 mM NaCl, 10 mM Na2HPO4, 2.7 mM
KCl, 2 mM KH2PO4, pH 7.4), centrifuged 5 min at 220 g and the
pellets stored at 80 C. Total extracts were prepared by resus-
pension of 1  107 cells in 1 ml lysis buffer (10 mM Tris-HCl pH 7.5,
10 mMNaCl, 2 mM EDTA, 5 mMMnSO4, 4 Halt Protease Inhibitor
(Thermo Fisher Scientiﬁc), 0.2 mg ml1 RNase A (Sigma-Aldrich),
500 U ml1 Cyanase (RiboSolutions, TX, USA), 0.1% Triton X-100)
followed by 30 min on ice. Extracts were supplemented with
NuPage LDS buffer (Thermo Fischer Scientiﬁc) and heated at 70 C
for 10 min. 105 cell equivalents were loaded on a 4e12% Bis-Tris
NuPage gel and blotted on nitrocellulose using the iBlot system
(ThermoFisher Scientiﬁc). 5-HT3 receptors were detected with
1:250 mouse monoclonal antibody (sc-390168; Santa Cruz
Biotechnology, TX, USA) and 1:10,000 goat anti-Mouse
IRDye800CW (925-32210; LI-COR Biosciences, NE, USA). CPSF-100
served as a loading control and was detected using 1:10,000 rab-
bit polyclonal antibody (kindly provided by Georges Martin &
Walter Keller, University of Basel) and 1:10,000 goat anti-Rabbit
IRDye680LT (925-68021, LI-COR Biosciences). Signals were
improved using SuperSignal Western Blot Enhancer (Thermo
Fischer Scientiﬁc) according to the manufacturer's instructions.
4.8. Modelling and docking
Using ClustalW, the protein sequence of the human 5-HT3A
subunit (accession: P46098) was aligned with the amino acid se-
quences extracted from ligand-bound AChBP crystal structures
(pdbid; 2WNC, 2YME). Five pentameric homology models were
generated usingModeller 9.13with default parameters and the best
model selected using Ramachandran plot analysis.
The three-dimensional and protonated structure of tropisetron
was constructed using Chem3D Pro v14.0 (CambridgeSoft, Cam-
bridge, UK) and was based on the crystal structure of N1-
methylated tropisetron extracted from the Cambridge Structural
Database (CSD access code BEGLEG). The generated ligand was
subsequently energy-minimised using the implemented MM2
force ﬁeld.
The binding site in the 5-HT3 receptor was deﬁned as being
within 10 Å of the centroid of the aromatic side-chain of W183, a
residue that is centrally located in the binding site and known to be
important for the binding of competitive ligands (Thompson et al.,
2010). Potential ligand-receptor interactions were identiﬁed in
each of the following four structures, A) a co-crystal structure of
tropisetron and AChBP (2WNC), B) a co-crystal structure of grani-
setron and AChBP (2YME), C) tropisetron docked into a 5-HT3 re-
ceptor homology model based upon 2WNC, and D) tropisetron
docked directly into 2YME. Tropisetron was docked using GOLDSuite v5.3 (The Cambridge Crystallographic Data Centre, Cam-
bridge, UK) with the GoldScore function and default settings.
During docking the carbonyl linker of tropisetron was deﬁned as
rigid as it is known that the planarity and rigidity of this bond is
crucial for high-afﬁnity binding (Hibert, 1994). For each of the two
homology models, ten docking poses were generated. For 2WNC
and 2YME the native poses were used. This analysis yielded 22
independent ligand poses. All residues within 5 Å of the ligand
were identiﬁed in each of the ligand poses and these residues and
their potential hydrogen bond interactions visualised using PyMol
v1.3.
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